Search results

...August | pmid = 19391150 | doi = 10.1002/syn.20647}}</ref> as well as a [[dopamine reuptake inhibitor]].{{Citation needed|date=April 2010}} [[fr:Kétamine]]

...eries for the ''[[in vitro]]'' reuptake of serotonin, norepinephrine and [[dopamine]]. This test, carried out by Jong-Sir Horng in May 1972,<ref name = Wong/> ...e neurotransmitters. 3 mg/kg increased only serotonin and did not increase dopamine and norepinephrine. The injection with 0.7 mg/kg fluoxetine corresponds to

...eptors without blocking the secretion of histamine. It also is a very weak dopamine antagonist.<ref>David J. McCann and Brett Roth, [http://www.emedicine.com/E [[fr:Prométhazine]]

...lase]], which converts [[L-DOPA|<small>L</small>-DOPA]] into [[dopamine]]. Dopamine is a precursor for [[norepinephrine]] (noradrenaline) and subsequently [[ep * It is converted to [[α-methylnorepinephrine]] by [[dopamine beta-hydroxylase]] (DBH). α-methylnorepinephrine is an [[agonist]] of pres

|ImageFile2=Dopamine-3d-CPK.png ...cyclopedia.com/doc/1O87-ventraltegmentalarea.html Reference for VTA.</ref> Dopamine is also a [[neurohormone]] released by the [[hypothalamus]]. Its main funct

...58:723–7. PMID 14186927.</ref> It appears to bind to [[dopamine receptor|dopamine D₂ receptors]] where it is a [[receptor antagonist]], and is als By inhibiting the action of [[dopamine]] ([[prolactin]]-inhibiting hormone), metoclopramide has sometimes been use

...rst oxidized to [[L-DOPA]], which is subsequently decarboxylated to give [[dopamine]]. Oxidation gives [[norepinephrine]], which is [[methylated]] to give epin ...ine precursors by enhancing the activity of [[tyrosine hydroxylase]] and [[dopamine-β-hydroxylase]], two key enzymes involved in catecholamine synthesis.{{Cit

...|author = Koyanagi S, Himukashi S, Mukaida K, Shichino T, Fukuda K|title = Dopamine D2-like receptor in the nucleus accumbens is involved in the antinociceptiv ...tle = Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitiz

...mode of therapeutic action involves norepinephrine and to a lesser degree dopamine, but it also releases some serotonin from presynaptic clefts. It should not [[fr:Éphédrine]]

...odiazepine dependence: focus on withdrawal syndrome. | journal = Ann Pharm Fr | volume = 67 | issue = 6 | pages = 408–13 | month= November| year = 2009 ...| issue = 6 | pages = 479–85 | pmid = 15029082 | url = http://www.masson.fr/masson/portal/bookmark?Global=1&Page=18&MenuIdSelected=106&MenuItemSelected

...29-2001}}</ref><ref name="Withers">{{cite journal |author=Withers LM, Cole FR, Nelson RB |title=Water-hemlock poisoning |journal=The New England Journal ...reated with intravenous [[fluid replacement]], but the administration of [[dopamine]] or [[norepinephrine]] may be required to restore blood pressure.<ref name

...and [[norepinephrine]] receptors. It is its action on the [[D2 receptor|D2 dopamine]] and [[5HT1A|5-HT_1A receptor]]s that can cause some side effect [[fr:Ergotamine]]

...e]], or as a [[norepinephrine releasing agent]] (NRA). It also acts as a [[dopamine releasing agent]] (DRA) to a lesser extent. [[fr:Phénylpropanolamine]]

...de via autoxidation and/or monoamine oxidase (MAO)-mediated deamination of dopamine and the subsequent reaction of accessible ferrous iron to generate highly t [[fr:Hémoglobine]]

**[[Dopamine]] [[fr:Inotropisme]]

*[[Dopamine]] [[fr:Chronotrope]]

...Merlo-Pich E, Mennini T, Samanin R | title= Evidence of the involvement of dopamine in the analgesic effect of nefopam. | journal= European Journal of Pharmaco [[fr:Néfopam]]

*[[N-arachidonoyl-dopamine]] (NADA) ...known [[monoamine]] [[neurotransmitter]]s, such as [[acetylcholine]] and [[dopamine]], endocannabinoids differ in numerous ways from them. For instance, they u

...released. By hijacking this process, exogenous opioids cause inappropriate dopamine release, and lead to aberrant [[synaptic plasticity]], which causes addicti ...runner's high; other candidates include [[epinephrine]], [[serotonin]], [[dopamine]] and more.

...no anticholinergic properties and is believed be devoid of any activity on dopamine, serotonin or histamin receptors. It is not addictive and tolerance does no [[fr:Analgésique]]

...thways involving the μ₁ [[opioid receptor]], precipitating a [[dopamine]] release in the [[nucleus accumbens]]. The effects of the drug can be supp ...apsulated in Soft Gelatin Capsules From Schedule I to Schedule II" (DEA 51 FR 17476-78). This permitted medical use of Marinol, albeit with the severe re

...aving an effect on multiple neurons. Examples of neuromodulators include [[dopamine]], [[serotonin]], [[acetylcholine]], [[histamine]] and others. ...ansmitter systems are the [[noradrenaline]] (norepinephrine) system, the [[dopamine]] system, the [[serotonin]] system and the [[cholinergic]] system. Drugs ta

...2, ideas were more concrete. Neurochemicals such as [[norepinephrine]], [[dopamine]], and [[serotonin]] were classified as "putative neurotransmitters in cert [[fr:Neurochimie]]

...ef name=missale>{{cite journal|author =Missale C, Nash SR. ''et al''|title=Dopamine receptors:from structure to function|journal=Physiol. Rev.|year=1998|volume [[fr:Transduction de signaux]]

...lesser degree than full agonists do. This slight release of serotonin and dopamine may contribute to the anti-depressant properties of buprenophine, especiall [[fr:Buprénorphine]]

...html NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2receptorsimplications for models of schizophrenia](20 ...= August | pmid = 19391150 | doi = 10.1002/syn.20647}}</ref> as well as [[dopamine reuptake inhibitor]]s.{{Citation needed|date=April 2010}}

| title = Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, | title=Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in

[[Category:Dopamine reuptake inhibitors]] [[fr:Dextrométhorphane]]

...s=284–9 |year=2005 |month=March |pmid=15745703 |doi= |url=http://www.edk.fr/reserve/revues/ms_papier/e-docs/00/00/06/F7/document_article.md}}</ref> and ...oxone]] and [[naltrexone]]. Dynorphin may play a role in the inhibition of dopamine release via [[kappa opioid receptor]]s.<ref>{{cite journal |author=Mamelak